Crusted scabies in two immunocompromised children: Successful treatment with oral ivermectin

Australasian Journal of Dermatology

Volumn 40, Issue 1, 1999, Pages 37-40

  Patel, Anita ^a   Hogan, Peter ^b   Walder, Brien ^a  

^a Sydney Children's Prnc Vfales H ^*  (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Chronic mucocutaneous candidiasis; Congenital T cell immunodeficiency; Norwegian scabies; Therapy

Indexed keywords

IVERMECTIN;

ARTICLE; CANDIDIASIS; CASE REPORT; CHILD; FEMALE; HUMAN; IMMUNE DEFICIENCY; MALE; ORAL DRUG ADMINISTRATION; SCABIES; SKIN INFECTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTINEMATODAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; IVERMECTIN; MALE; SCABIES; TREATMENT OUTCOME;

EID: 0033063789     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.1999.00314.x     Document Type: Article

References (14)

1. Del Giudice P, Carles M. Couppie P et al. Successful treatment of crusted (Norwegian) scabies with ivermectin in two patients with human immunodeficiency virus infection (letter). Br.J. Dcrniatol. 1996; 135: 494-5.
2. Meinking T, Taplin D, Hermida J L et al. The treatment of scabies with ivermectin. N. Engl. J. Med. 1995; 333: 26-30.
3. Corbett EL, Crossley I, Holten J, Levell N, Miller R, De Cook KM. Crusted (Norwegian) scabies in a specialist HIV unit; successful use of ivermectin and failure to prevent nosocomial infection. Genitourin. Med. 1996; 72: 115-17.
4. Ottesen EA, Campbell VVC. Review: Ivermectin in human medicine. J. Antimicrob. Chemother. 1995; 34: 195-203.
5. Burnham GM. Adverse reactions to ivermectin for onchocerciasis: Results of a placebo controlled, double-blind trial in Malawi. Trans. R. Soc. Trop. Med. Hyg. 1993; 87: 313-17.
6. Nguyen NL, Moulia-Pelat JP, Glaziou P, Martin PM, Cartel JL. Advantages of ivermectin at a single dose of 400 (ig/kg compared with 100 ng/kg for community treatment of lymphatic filariasis in Polynesia. Trans. R. Soc. Trop. Med. Hyg. 1994; 88: 461-4.
7. Marty P. Gari-Toussaint M, Le Fichoux Y, Gaxotte P. Efficacy of ivermectin in the treatment of an epidemic of sarcoptic scabies. Ann. Trop. Med. Parasitol. 1994; 88: 453.
8. Glaziou P, Nguyen NL, Moulia-Pelat JP, Cartel JL, Martin PM. Efficacy of ivermectin for the treatment of head lice (pediculosis capitis). Trop. Med. Parasitol. 1994; 45: 253-4.
9. Glaziou P, Cartel JL, Alzieu P, Briot C, Moulia-Pelat JP, Martin PM. Comparison of ivermectin and benzyl benzoate for the treatment of scabies. Trop. Med. Parasitai 1993; 44: 331-2.
10. Barkwell R, Shields S. Deaths associated with ivermectin treatment of scabies. Lancet 1997; 349: 1144-5.
11. Sullivan JR, Watt G, Barker B. Successful use of ivermectin in the treatment of endemic scabies in a nursing home. Australas. J. Dermatol 1997; 38: 137-40.
12. Franz T, Lehman P, Franz S, Guin JD. Comparative percutaneous absorption of lindane and permethrin. Arch. Dermatol. 1996; 132: 901-5.
13. Soboslay PT, Luder CG. Hoffmann WH et al Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Thltype responses with subclinical Onchocerca volvulus infection. Clin. Exp. Immunol. 1994; 96: 238-44.
14. Soboslay PT, Dreweck CM, Hoffmann WH étal. Ivermectinfacilitated immunity in onchocerciasis: Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment. Clin. Exp. Immunol. 1992; 89: 407-13.